Eszol Dosage/Direction for Use

Treatment schedules in adults are given as follows: Indication: Vulvovaginal candidosis.
Dose¹: 200 mg twice daily for 1 day.
Indication: Pityriasis versicolor.
Dose¹: 200 mg once daily for 7 days.
Indication: Tinea corporis, tinea cruris.
Dose¹: 100 mg once daily for 15 days or 200 mg once daily for 7 days.
Indication: Tinea pedis, tinea manuum.
Dose¹: 100 mg once daily for 30 days.
Indication: Oropharyngeal candidosis.
Dose¹: 100 mg once daily for 15 days.
Remarks: Increase dose to 200 mg once daily for 15 days in AIDS or neutropenic patients because of impaired absorption in these groups.
Indication: Onychomycosis (toenails with or without fingernail involvement).
Dose¹: 200 mg once daily for 3 months.
For skin, vulvovaginal and oropharyngeal infections, optimal clinical and mycological effects are reached 1 - 4 weeks after cessation of treatment and for nail infections, 6 - 9 months after the cessation of treatment. This is because elimination of itraconazole from skin, nails and mucous membranes is slower than from plasma.
The length of treatment for systemic fungal infections should be dictated by the mycological and clinical response to therapy: Indication: Aspergillosis.
Dose¹: 200 mg once daily.
Remarks: Increase dose to 200 mg twice daily in case of invasive or disseminated disease.
Indication: Candidosis.
Dose¹: 100-200 mg once daily.
Remarks: Increase dose to 200 mg twice daily in case of invasive or disseminated disease.
Indication: Non-meningeal Cryptococcosis.
Dose¹: 200 mg once daily.
Indication: Cryptococcal meningitis.
Dose¹: 200 mg twice daily.
Remarks: See Precautions.
Indication: Histoplasmosis.
Dose¹: 200 mg once daily-200 mg twice daily.
Indication: Maintenance in AIDS.
Dose¹: 200 mg once daily.
Remarks: See note on impaired absorption as follows.
Indication: Prophylaxis in neutropenia.
Dose¹: 200 mg once daily.
Remarks: See note on impaired absorption as follows.
¹The duration of treatment should be adjusted depending on the clinical response.
Impaired absorption in AIDS and neutropenic patients may lead to low itraconazole blood levels and lack of efficacy. In such cases, blood level monitoring and if necessary, an increase in itraconazole dose to 200 mg twice daily, is indicated.
Special population: Paediatrics: Clinical data on the use of Eszol in paediatric patients are limited. The use of Eszol in paediatric patients is not recommended unless it is determined that the potential benefit outweighs the potential risks. See Precautions.
Elderly: Clinical data on the use of Eszol in elderly patients are limited. It is advised to use Eszol in these patients only if it is determined that the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. See Precautions.
Renal impairment: The oral bioavailability of itraconazole may be lower in patients with renal insufficiency, a dose adjustment may be considered. See Precautions.
Hepatic impairment: Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. (See Pharmacology: Pharmacokinetics: Special populations: Hepatic impairment under Actions).
Mode of administration: Eszol is for oral administration and must be taken immediately after a meal for maximal absorption.